表紙
市場調查報告書

結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24) - 開發中產品分析

Connective Tissue Growth Factor - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 358690
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24) - 開發中產品分析 Connective Tissue Growth Factor - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 83 Pages
簡介

結締組織生長因子 (CTGF) ,又稱為CCN2,是細胞外矩陣相關的肝素結合蛋白質的CCN家族的矩陣細胞的蛋白質。

本報告提供結締組織生長因子 (胰島素樣成長因素結合蛋白質8,肥大軟骨細胞特別蛋白質24)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的評估

  • 各單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • FibroGen, Inc.
  • RXi Pharmaceuticals Corporation

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2015TDB

Summary

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Connective tissue growth factor (CTGF), also known as CCN2 is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins. CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis (TGF-beta-dependent). This includes fibrosis of major organs, fibroproliferative diseases, and scarring. CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing.

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Genetic Disorders, Oncology, Respiratory, Dermatology, Musculoskeletal Disorders, Cardiovascular, Genito Urinary System And Sex Hormones, Metabolic Disorders, Ophthalmology and Toxicology which include indications Liver Fibrosis, Idiopathic Pulmonary Fibrosis, Duchenne Muscular Dystrophy, Fibrosis, Hypertrophic Scars, Non-Alcoholic Steatohepatitis (NASH), Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Cirrhosis, Diabetic Nephropathy, Keloids, Liver Cancer, Myocardial Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Scar and Wet (Neovascular / Exudative) Macular Degeneration.

The latest report Connective Tissue Growth Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
  • The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
  • BLR Bio LLC
  • FibroGen Inc
  • InnoBioscience LLC
  • Liminal BioSciences Inc
  • OliX Pharmaceuticals Inc
  • Phio Pharmaceuticals Corp
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
  • BLR-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLR-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IB-DMD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OLX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OLX-201A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OLX-301D - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OLX-701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pamrevlumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBI-4050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RXI-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
  • Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmonary Arterial Hypertension
  • Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050
  • Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
  • Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
  • Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
  • Oct 23, 2019: FibroGen announces first patient dosed in LAPIS, a phase 3 clinical trial of Pamrevlumab for the treatment of patients with locally advanced pancreatic cancer
  • Sep 30, 2019: FibroGen announces publication in the Lancet Respiratory Medicine of positive Pamrevlumab efficacy and safety data for the praise phase 2 study in Idiopathic Pulmonary Fibrosis
  • Jul 22, 2019: FibroGen announces first patient dosed in ZEPHYRUS, a phase 3 clinical trial of pamrevlumab for the treatment of patients with idiopathic pulmonary fibrosis
  • Jun 28, 2019: FibroGen to present interim phase 2 data on pamrevlumab in subjects with duchenne muscular dystrophy at the parent project muscular dystrophy 2019 annual conference
  • Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
  • May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
  • Apr 15, 2019: FibroGen receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the treatment of Duchenne Muscular Dystrophy
  • Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
  • Sep 12, 2018: FibroGen receives Fast Track designation from the U.S. FDA for Pamrevlumab for the Treatment of idiopathic pulmonary fibrosis
  • Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by BLR Bio LLC, H2 2019
  • Pipeline by FibroGen Inc, H2 2019
  • Pipeline by InnoBioscience LLC, H2 2019
  • Pipeline by Liminal BioSciences Inc, H2 2019
  • Pipeline by OliX Pharmaceuticals Inc, H2 2019
  • Pipeline by Phio Pharmaceuticals Corp, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top